New Zealand approves use of MDMA to treat severe PTSD
Quick Look
- Medsafe, New Zealand's regulatory agency, has authorized two psychiatrists to prescribe pharmaceutical-grade MDMA for the treatment of severe PTSD, making the country the second in the world to approve the use of the substance for this purpose, after Australia in 2023.
- The decision was supported by Deputy Prime Minister David Seymour, who highlighted the potential of psychedelic-assisted therapy.
AI-generated summary
Why It Matters
New Zealand followed Australia in approving the medicinal use of MDMA to treat PTSD, after the US FDA rejected the application in 2024 due to a lack of sufficient evidence.
Two New Zealand psychiatrists received authorization this Friday (4) to prescribe pharmaceutical-grade MDMA to people with severe post-traumatic stress disorder (PTSD).
The decision by Medsafe, New Zealand's medicines regulatory agency, makes the country the second in the world to approve the use of this recreational drug for the treatment of PTSD, after Australia adopted a similar measure in 2023.
"PTSD destroys lives and is difficult to treat," said Deputy Prime Minister David Seymour, who last year supported approval for the use of hallucinogenic mushrooms to treat people with severe depression.
"MDMA can be very effective in treating the condition through psychedelic-assisted therapy. New Zealand is committed to expanding access to innovative treatments," he added.
PTSD is a mental health disorder that develops after a person experiences or is threatened by traumatic events, such as death, military combat, or sexual assault.
In the United States, clinical trials are underway. In 2024, the Food and Drug Administration (FDA) rejected legalizing the medicinal use of MDMA, claiming there was insufficient evidence of its safety and effectiveness.
What to Watch
AI outlook — possibilities, not facts
Other countries may follow New Zealand and Australia in approving MDMA for treating PTSD based on early results.
Possible · Within months
Open Questions
- How many patients will initially be treated with this authorization?
- What will be the monitoring and dosing protocol for the use of MDMA?
- Are there plans to expand authorization to other healthcare professionals beyond the two initially authorized psychiatrists?
